Shots:
- Adaptimmune to receive $150M up front, $150M as additional payments over 5yrs., $3B+ as research, development, regulatory & commercial milestones along with royalties across multiple programs
- Adaptimmune can opt for 50-50 US profit/cost-share for off-the-shelf products. If it elects to opt-in, Adaptimmune will share 50% of profits & losses from US sales & receive ex-US regulatory & sales-based milestones along with royalties on ex-US net sales
- Genentech will be responsible for the input TCRs, clinical development & commercialization. Adaptimmune will lead the development of clinical candidates using its iPSC-derived allogeneic platform to produce iT cells
Click here to read full press release/ article | Ref: Globe Newswire | Image: Adaptimmune
The post Genentech Signs a License Agreement with Adaptimmune to Develop and Commercialize Cancer-Targeted Allogeneic T-cell Therapies first appeared on PharmaShots.
